From MarketBeat:



In recent news, Halozyme Therapeutics (NASDAQ: HALO) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating, with a consensus rating of “Moderate Buy” and an average price target of $52.73. Additionally, the company reported a positive quarterly earnings performance with an EPS of $0.69, topping the consensus of $0.67.

Furthermore, SVP Michael J. Labarre sold 10,000 shares of the company’s stock, and several large investors have added or reduced their stakes in HALO. Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices, with products based on the patented recombinant human hyaluronidase enzyme enabling the delivery of injectable biologics, small molecules, and fluids. However, Halozyme Therapeutics did not make the list of top-rated analysts’ five recommended stocks.

This news article was generated by narrative science technology and financial data to provide readers with fast and accurate reporting from MarketBeat, with insights into Halozyme Therapeutics and the current state of the pharmaceutical industry.



Read more: Halozyme Therapeutics (NASDAQ:HALO) Upgraded to “Buy” by StockNews.com